CN104758305A - Medical application of notoginsenoside Ft1 - Google Patents
Medical application of notoginsenoside Ft1 Download PDFInfo
- Publication number
- CN104758305A CN104758305A CN201410002634.0A CN201410002634A CN104758305A CN 104758305 A CN104758305 A CN 104758305A CN 201410002634 A CN201410002634 A CN 201410002634A CN 104758305 A CN104758305 A CN 104758305A
- Authority
- CN
- China
- Prior art keywords
- arasaponin
- application
- preparation
- compositions
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of medicine science, in particular to medical application of notoginsenoside Ft1. Animal experimental results prove that the notoginsenoside Ft1 can effectively promote wound healing of diabetics, so that the notoginsenoside has great significance on treating diabetic gangrene.
Description
Technical field
The present invention relates to Medicines and Health Product field, particularly relate to the medical usage of a kind of arasaponin Ft1.
Background technology
Diabetes are metabolic diseases of serious threat human health, have become the disease of the fourth-largest easy causing death after cardiovascular, tumor, acquired immune deficiency syndrome (AIDS).Statistical data shows the current whole world 2.85 hundred million diabeticss, predicts the year two thousand thirty global diabetics and will reach 4.39 hundred million, and the complication that diabetes cause then becomes patient and disables and lethal main cause.In many complication of diabetes, diabetics wound-healing abilities is impaired is diabetes typical complication, if chronic damage and ulcer occur in foot, then likely cause diabetic foot, severe patient even causes amputation, this has become the highest disease of diabetics admission rate, it is reported the amputation that the whole world just has an example to cause because of diabetes in every 30 seconds.But, still there is no effective Therapeutic Method up to now.
Diabetics, when blood glucose is too high, cell is interior, all likely dewatering in extracellular, affects wound healing.Meanwhile, blood sugar in diabetic patients controls bad, and the ability of body eliminating bacteria can reduce.Hyperglycemia can reduce cell transport oxygen to the ability of tissue, causes blood circulation bad, also affects wound healing.Blood glucose raises and easily causes microangiopathies, infringement blood vessel and nerve, causes ulcer to be difficult to healing.
Therefore, seek to promote that the medicine of the wound healing of diabetes is one of focus of diabetes area research always.Therefore, develop a kind of product for diabetics wound healing and have market prospect very much.
Arasaponin Ft1(Notoginsenoside Ft1) be a kind of natural saponins compound, be mainly present in Radix Notoginseng.Research finds, arasaponin has the effects such as blood fat reducing, antitumor, elimination oxygen-derived free radicals, antioxidation.
Summary of the invention
Object of the present invention aims to provide the new medical usage of a kind of arasaponin Ft1.
Specifically, the invention provides the application of a kind of arasaponin Ft1 in the obvious compositions promoting the formation of promoting epidermization and granulation tissue of preparation.
The invention provides the application of a kind of arasaponin Ft1 in the compositions of preparation shortening wound healing time.
The invention provides the application of a kind of arasaponin Ft1 in the compositions of preparation promotion diabetic wound healing.
The invention provides the application of a kind of arasaponin Ft1 in the compositions of preparation treatment diabetic foot.
The invention provides a kind of arasaponin Ft1 preparation prevent diabetes patient's wound be difficult to heal compositions in application..
The invention provides the application of a kind of arasaponin Ft1 in preparation prevents diabetes medicine or food or cosmetics or articles for washing or toothpaste that patient's wound is difficult to heal.
The invention provides a kind of arasaponin Ft1 and prepare the application prevented diabetes in sufficient medicine or food.
The invention provides the application that a kind of arasaponin Ft1 treats in preparation or prevents diabetes in the compositions of gangrene.
The invention provides the application that a kind of arasaponin Ft1 prevents diabetes in the medicine of gangrene or food or cosmetics or articles for washing or toothpaste in preparation.
The details of various aspects of the present invention is able to detailed description by chapters and sections subsequently.By hereafter and the description of claim, feature of the present invention, object and advantage will be more obvious.
Accompanying drawing explanation
Fig. 1 embodies the impact of Ft1 on db/db mice wound healing;
Fig. 2 embodies the impact of Ft1 on the average healing days of db/db mice wound;
The average healing days that Fig. 3 embodies Ft1 is obviously better than blank group;
Detailed description of the invention
Appearance part of the present invention is based on so unexpected discovery: arasaponin Ft1 obviously can promote the formation of promoting epidermization and granulation tissue, significantly shortens the time of wound healing, effectively promotes the wound healing of diabetes.Therefore, arasaponin Ft1 can be used for the healing for the treatment of the chronic wounds such as diabetic foot.
And then the invention provides arasaponin Ft1 and prepare application in the treatment medicine of diabetes wound healing or food.
The molecular formula of arasaponin Ft1 of the present invention is: C
47h
80o
17, molecular weight is: 916.54, and its structural formula is as follows:
R=H;R
1=Xyl
1-
2Glc
1-
2Glc
Arasaponin Ft1 of the present invention to buy from Sigma chemical company, Man Site bio tech ltd, Chengdu etc. by commercial sources and obtains, or is separated from arasaponin by the conventional method of this area and obtains.Its purity all meets medicinal standard.
So that arasaponin Ft1 of the present invention is made medicine.Arasaponin Ft1 of the present invention can be used alone or uses with the form of pharmaceutical composition.Pharmaceutical composition comprises arasaponin Ft1 of the present invention as active component and pharmaceutically suitable carrier.Preferably, pharmaceutical composition of the present invention contains the arasaponin Ft1 of the present invention as active component of 0.1-99.9% percentage by weight." pharmaceutically suitable carrier " can not destroy the pharmaceutical active of arasaponin Ft1 of the present invention, simultaneously its effective dose, and consumption when can play pharmaceutical carrier effect is to human non-toxic.
Described pharmaceutically suitable carrier includes but not limited to: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self-emulsifying drug delivery system, tween or other surfactants, serum albumin, buffer substance are if phosphate, glycine, sorbic acid, water, salt, electrolyte are as sulfate protamine, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid partial glyceride mixtures etc.
Other conventional excipient substances are as binding agent (as microcrystalline Cellulose), filler (as starch, glucose, Lactis Anhydrous and lactose beadlet), disintegrating agent (as cross-linked pvp, crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricant (as magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, excipient, diluent, wetting agent etc.
Arasaponin Ft1 of the present invention and its pharmaceutical composition can by the preparations of this area conventional method and can by intestinal or non-bowel or topical routes.Oral formulations comprises capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.; Non-intestinal drug delivery agent comprises injection etc.; Local administration preparation comprises cream, patch, ointment, spray etc.Be preferably oral formulations.
The route of administration of arasaponin Ft1 of the present invention and its pharmaceutical composition can be oral, Sublingual, percutaneous, through muscle or subcutaneous, mucocutaneous, vein, urethra, vagina etc.
Except making medicine, also can add the various food additive such as antioxidant, pigment, enzyme preparation in arasaponin Ft1 of the present invention, make health food by the conventional method of this area.Arasaponin Ft1 of the present invention can be added in toothpaste the health-care toothpaste made and can prevent and treat gingival hemorrhage in addition.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, the usually conveniently conditioned disjunction condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percent, ratio, ratio or number by weight.
Unless otherwise defined, all specialties used in literary composition and scientific words and one skilled in the art the same meaning be familiar with.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The use that better implementation method described in literary composition and material only present a demonstration.
The above-mentioned feature that the present invention mentions, or the feature that embodiment is mentioned can combination in any.All features that patent specification discloses can with any composition forms and use, each feature disclosed in description, anyly can provide identical, alternative characteristics that is impartial or similar object replaces.Therefore apart from special instruction, the feature disclosed is only general example that is impartial or similar features.
Detailed description of the invention
1, experiment material
1.1 medical material
Arasaponin Ft1(molecular weight: 917.13, HPLC purity >=99%, institute of Chinese materia medica)
1.2 laboratory animal
The db/db female mice (12 weeks) of body weight 50 ± 5g, is provided by Shanghai Univ. of Traditional Chinese Medicine's Experimental Animal Center, the animal quality certification number: SCXK (capital) 2011-0012.Be placed in conventional feeding environment, sub-cage rearing, ad lib and drinking-water.
2, experimental technique
2.1 diabetic lesions models are set up
Adopt the modeling method (Nature Protocols, 2013,8:302-309) in document, after isoflurane anesthesia, shave off skin of back, depilatory cream loses hair or feathers, conventional transdermal is sterilized, and uses the card punch of diameter 6mm to cut a circular incision in spinal column both sides, back respectively, deeply reaches fascia.For preventing wound from automatically shrinking, be stained with silicone gasket (0.5mm thick, internal diameter 9mm, external diameter 18mm) respectively at its edge, and and skin closure.The same day was counted postoperative 0th day in operation, by that analogy.
2.2 grouping and medications
Blank group: aseptic ultra-pure water (15uL/wound)
Positive controls: VEGF (VEGF) (1.0mg/mL, 15uL/wound).
Medication group: arasaponin Ft1 (15mg/mL, 15uL/wound).
Often organize 10, perform the operation the same day, and within every two days, be administered once, after administration, adopt biological permeability plastic film covering wound.
2.3 wound healings are observed:
Performed the operation the same day, and every other day, used digital camera to gather wound photo at level altitude, go out wound area by Image J computed in software.
2.4 statistical analysis
All experimental datas all repeat 3 times, result represents with mean+SD, adopt SPSS 13.0 statistical software to adopt one way analysis of variance (One-way ANOVA) and LSD inspection to experimental data, P<0.05 is that statistically difference has significance.
3, result
3.1 arasaponin Ft1 are on the impact of db/db mice wound healing.
Table 1. arasaponin Ft1 is on the impact of db/db mice wound area
Fig. 1 embodies the impact of arasaponin Ft1 on db/db mice wound healing, as seen from Figure 1, postoperative 6th day started to the 16th day, and the wound area of arasaponin Ft1 administration group db/db mice is significantly less than blank group, and both have significant difference (P<0.05).
Fig. 2 is visible, and arasaponin Ft1 administration group and blank group were the wound healing situation of 0,8,12,14 day.
Fig. 3 is visible, and the average healing days of arasaponin Ft1 administration group db/db mice wound is 14.8 days, significantly lower than blank group (21.2 days) (P<0.001).
To sum up result of study shows, arasaponin Ft1 can promote the wound healing of diabetic mice effectively, significantly shortens the time of wound healing.
Many aspects involved in the present invention have been done and have as above been set forth.It is to be understood, however, that put before not departing from spirit of the present invention, those skilled in the art can carry out equivalent change and modification to it, and described change and modification fall into the coverage of the application's claims equally.
Claims (9)
1. arasaponin Ft1 obviously promotes the application in the compositions of the formation of promoting epidermization and granulation tissue in preparation.
2. arasaponin Ft1 shortens the application in the compositions of wound healing time in preparation.
3. arasaponin Ft1 promotes the application in the compositions of diabetic wound healing in preparation.
4. the application of arasaponin Ft1 in the compositions of preparation treatment diabetic foot.
5. arasaponin Ft1 preparation prevent diabetes patient's wound be difficult to heal compositions in application..
6. the application of arasaponin Ft1 in preparation prevents diabetes medicine or food or cosmetics or articles for washing or toothpaste that patient's wound is difficult to heal.
7. arasaponin Ft1 is preparing the application prevented diabetes in sufficient medicine or food.
8. arasaponin Ft1 is in the application preparing treatment or prevent diabetes in the compositions of gangrene..
9. the application that prevents diabetes in the medicine of gangrene or food or cosmetics or articles for washing or toothpaste in preparation of arasaponin Ft1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410002634.0A CN104758305A (en) | 2014-01-03 | 2014-01-03 | Medical application of notoginsenoside Ft1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410002634.0A CN104758305A (en) | 2014-01-03 | 2014-01-03 | Medical application of notoginsenoside Ft1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104758305A true CN104758305A (en) | 2015-07-08 |
Family
ID=53640635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410002634.0A Pending CN104758305A (en) | 2014-01-03 | 2014-01-03 | Medical application of notoginsenoside Ft1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758305A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108014118A (en) * | 2017-12-25 | 2018-05-11 | 上海中医药大学 | A kind of purposes of notoginsenoside Ft1 |
| CN115252631A (en) * | 2022-06-24 | 2022-11-01 | 上海市第六人民医院 | Application of pseudo-ginseng extract in preparation of medicine for treating diabetic nephropathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
| CN102579537A (en) * | 2012-03-12 | 2012-07-18 | 赵太明 | Medicament for treating diabetic foot and deep ulcer |
-
2014
- 2014-01-03 CN CN201410002634.0A patent/CN104758305A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
| CN102579537A (en) * | 2012-03-12 | 2012-07-18 | 赵太明 | Medicament for treating diabetic foot and deep ulcer |
Non-Patent Citations (1)
| Title |
|---|
| KAIKAI SHEN ET AL.: ""Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways"", 《BIOCHEMICAL PHARMACOLOGY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108014118A (en) * | 2017-12-25 | 2018-05-11 | 上海中医药大学 | A kind of purposes of notoginsenoside Ft1 |
| CN108014118B (en) * | 2017-12-25 | 2019-12-03 | 上海中医药大学 | A kind of purposes of notoginsenoside Ft1 |
| CN115252631A (en) * | 2022-06-24 | 2022-11-01 | 上海市第六人民医院 | Application of pseudo-ginseng extract in preparation of medicine for treating diabetic nephropathy |
| CN115252631B (en) * | 2022-06-24 | 2024-05-14 | 上海市第六人民医院 | Application of pseudo-ginseng extract in preparation of medicine for treating diabetic nephropathy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885857B (en) | Extraction method of periplaneta americana extract for treating peptic ulcer | |
| CN105582028A (en) | Use of antrodia camphorata for treating diseases | |
| CN114306206A (en) | External traditional Chinese medicine composition for treating thyroid nodule and preparation method and application of external traditional Chinese medicine gel plaster | |
| CN104758305A (en) | Medical application of notoginsenoside Ft1 | |
| EP3884942B1 (en) | Use of bulleyaconitine a for treating skin disorders | |
| CN104758304A (en) | Medical application of notoginsenoside R1 | |
| CN104940291A (en) | Composition for preventing and treating honeybee microsporidiosis and use thereof | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN104257676B (en) | One kind treats the migrainous compositionss of asthenic cold type | |
| CN107281242A (en) | Pill of Eight Treasures and its preparation are preparing the application in suppressing inflammatory tissue anti-proliferative agent | |
| CN105012325A (en) | Medical application of notoginsenoside ST-4 | |
| CN105012315A (en) | Medical application of 20(R)-protopanoxadiol | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN102188647B (en) | Chinese medicinal composition for treating ulcer and inflammation of digestive systems and preparation method thereof | |
| CN105232559A (en) | Medical applications of 20(S)-protopanoxadiol | |
| CN105707397A (en) | Heathy vitamin candy | |
| US20190110512A1 (en) | Food composition for relieving symptoms of viral diseases | |
| CN105853463A (en) | Traditional Chinese medicinal preparation for treating carbuncle ulcer and promoting muscle growth as well as preparing method and application thereof | |
| CN109381466A (en) | Promote the therapeutic agent of diabetic wound healing | |
| CN106420815A (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN103977084B (en) | Chinese medicine preparation of a kind of inducing diuresis for treating strangurtia and preparation method thereof | |
| CN102948663A (en) | Rana japonica oil granules and preparation method thereof | |
| CN106727958A (en) | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof | |
| CN103705618B (en) | Treat beriberic medicine | |
| Panda et al. | Zinc in Ayurvedic herbo-mineral products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150708 |
|
| RJ01 | Rejection of invention patent application after publication |